Literature DB >> 24019655

Iodine-131MIBG SPECT/CT in neuroendocrine tumours: An institutional experience.

Priyanka Verma1, Julie Hephzibah, Nylla Shanthly, Regi Oommen.   

Abstract

CONTEXT: Radiolabelled metaiodobenzylguanidine (MIBG) is commonly used for imaging of neuroendocrine tumors (NETs). The hybrid imaging with single photon emission computerized tomography/computerized tomography (SPECT/CT) co-registration can give that additional edge to this functional imaging modality. AIMS: To study the additional value of (131)I-MIBG SPECT/CT scintigraphy in evaluation of NETs. SETTINGS AND
DESIGN: We performed a retrospective study of the scintigraphic data of patients referred to our department for detection and follow-up of NETs from 2004 to 2008.
MATERIALS AND METHODS: Total number of studies were 370. Twenty-eight patients with equivocal findings on planar imaging had undergone additional SPECT/CT imaging. The contribution made by SPECT/CT imaging in these studies was analyzed.
RESULTS: In 27 of 28 cases, SPECT/CT provided vital additional information.
CONCLUSIONS: We concluded that SPECT/CT co-registration helps in exclusion, identification, and localization of primary and metastatic NETs. It differentiates physiological from pathological tracer distribution. It helps increase the confidence in reporting, especially in equivocal findings on planar imaging.

Entities:  

Keywords:  Radiolabelled metaiodobenzylguanidine; neuroendocrine tumors; single photon emission computerized tomography/computerized tomography

Year:  2012        PMID: 24019655      PMCID: PMC3759086          DOI: 10.4103/0972-3919.115396

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


  11 in total

Review 1.  Functional-anatomical image fusion in neuroendocrine tumors.

Authors:  Orazio Schillaci
Journal:  Cancer Biother Radiopharm       Date:  2004-02       Impact factor: 3.099

2.  131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

Review 3.  Imaging of neuroendocrine tumors.

Authors:  Vittoria Rufini; Maria Lucia Calcagni; Richard P Baum
Journal:  Semin Nucl Med       Date:  2006-07       Impact factor: 4.446

4.  Value of combined XCT/SPECT technology for avoiding false positive planar (123)I-MIBG scintigraphy.

Authors:  S Ozer; G Dobrozemsky; O Kienast; M Beheshti; A Becherer; B Niederle; F Kainberger; R Dudczak; A Kurtaran
Journal:  Nuklearmedizin       Date:  2004-10       Impact factor: 1.379

Review 5.  Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors.

Authors:  A J McEwan; B Shapiro; J C Sisson; W H Beierwaltes; D M Ackery
Journal:  Semin Nucl Med       Date:  1985-04       Impact factor: 4.446

Review 6.  Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors.

Authors:  E Bombardieri; E Seregni; C Villano; A Chiti; E Bajetta
Journal:  Q J Nucl Med Mol Imaging       Date:  2004-06       Impact factor: 2.346

7.  Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma.

Authors:  Katia Rozovsky; Benjamin Z Koplewitz; Yodphat Krausz; Shoshana Revel-Vilk; Michael Weintraub; Roland Chisin; Martine Klein
Journal:  AJR Am J Roentgenol       Date:  2008-04       Impact factor: 3.959

Review 8.  The diagnosis and medical management of advanced neuroendocrine tumors.

Authors:  Gregory A Kaltsas; G Michael Besser; Ashley B Grossman
Journal:  Endocr Rev       Date:  2004-06       Impact factor: 19.871

9.  Outcome of [131I]metaiodobenzylguanidine therapy of neuroblastoma: seven years after.

Authors:  G Hör; F D Maul; B Kornhuber; D Schwabe; J Hesse; K H Manegold; R P Baüm; V Gerein
Journal:  J Nucl Biol Med       Date:  1991 Oct-Dec

Review 10.  Imaging of neuroendocrine tumors.

Authors:  Eric P Tamm; E Edmund Kim; Chaan S Ng
Journal:  Hematol Oncol Clin North Am       Date:  2007-06       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.